Showing 1‐10 of 500
Corporate
17 Apr 2024
Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon
Basel, Switzerland, 17 April 2024 – Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a EUR 1 billion...
Corporate
03 Apr 2024
Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports
Annual General Meeting will take place on 8 May 2024 at the Congress Center in Basel, Switzerland Albert M. Baehny will not stand for re-election as Chairman of the Board of...
Corporate
02 Apr 2024
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
Wolfgang Wienand, currently CEO of Swiss CDMO Siegfried Holding AG, will become Chief Executive Officer of Lonza in the summer of 2024 Albert M. Baehny will retire from Lonza...
Corporate
20 Mar 2024
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche
Lonza has signed an agreement to acquire the Genentech manufacturing facility in Vacaville (US) from Roche for USD 1.2 billion in cash
Corporate
26 Jan 2024
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza
Corporate
26 Jan 2024
Lonza Delivers Solid 2023 Performance with 10.9% CER Sales Growth and 29.8% CORE EBITDA Margin
Lonza Delivers Solid 2023 Performance with 10.9% CER Sales Growth and 29.8% CORE EBITDA Margin
Corporate
06 Nov 2023
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
Basel, Switzerland, 06 November 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CHF 400 million...
Corporate
17 Oct 2023
Capital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
At its Capital Markets Day, Lonza outlined its Mid-Term Guidance for 2024 to 2028, including: 11–13% sales growth, 32–34% CORE EBITDA margin and double-digit ROIC Outlook 2023:...
Biologics
16 Oct 2023
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
New agreement to establish global commercial manufacturing capacity for Vaxcyte's PCV candidates, VAX-24 and VAX-31, in adult and pediatric populations Expanded collaboration...
Biologics
13 Oct 2023
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
The new cGMP filling line at Lonza’s Stein (CH) site will enable handling and filling of bioconjugates for commercial supply Expansion of filling capacity will enhance Lonza's...
1 2 3 4 ... 50 >
Media Advisories

Updates for media on the latest products, offerings and developments across our business.

View all